characteristics.text: SAMN35346641
characteristics.characteristic: External Id
characteristics.text: Leukemia Biology, Manchester Institute, Cancer Research UK
characteristics.characteristic: INSDC center name
characteristics.text: 2025-01-22T00:40:37.297Z
characteristics.characteristic: INSDC first public
characteristics.text: 2025-01-22T00:40:37.297Z
characteristics.characteristic: INSDC last update
characteristics.text: SRS17808521
characteristics.characteristic: INSDC secondary accession
characteristics.text: live
characteristics.characteristic: INSDC status
characteristics.text: Generic
characteristics.characteristic: NCBI submission model
characteristics.text: Generic.1.0
characteristics.characteristic: NCBI submission package
characteristics.text: SRS17808521
characteristics.characteristic: SRA accession
characteristics.text: primary AML
characteristics.characteristic: cell type
characteristics.text: anti-MED1 (A300-793A, Bethyl, Cambridge, UK; 1μg per ChIP)
characteristics.characteristic: chip antibody
characteristics.text: missing
characteristics.characteristic: collection_date
characteristics.text: missing
characteristics.characteristic: geo_loc_name
characteristics.text: Homo sapiens
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/NCBITaxon_9606
characteristics.characteristic: organism
characteristics.text: Fujioka Cells
characteristics.characteristic: source_name
characteristics.text: TS105_05_Fujioka-MED1
characteristics.characteristic: title
characteristics.text: Cultured in RPMI 1640 medium (Sigma Aldrich) supplemented with 2mM L-Glutamine (Life Technologies) and 10% fetal bovine serum (Sigma Aldrich).
characteristics.characteristic: treatment